Furthermore, anti-TNF biosimilar alternatives have not yet been available long enough to have been included in many health economic assessments, although in Europe biosimilars prescribed for the management of IBD allow savings of 15–75% compared with the original compounds [35]. This evidence concerns the gene TNF and inflammatory bowel disease.